51. Scleroderma
466 clinical trials,   536 drugs   (DrugBank: 142 drugs),   110 drug target genes,   210 drug target pathways
Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00253331 (ClinicalTrials.gov) | November 2004 | 13/11/2005 | Lab Study of MQX-503 in Treatment of Raynaud's | Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon | Raynaud Disease;Raynaud Disease Secondary to Scleroderma;Raynaud Secondary to Other Autoimmune Disease | Drug: topical organogel with nitroglycerin | MediQuest Therapeutics | NULL | Completed | 18 Years | 80 Years | Both | 36 | Phase 2;Phase 3 | United States |